Phase 2 Endometrial Cancer Trial, Recruiting NCT06562166 Sponsor: Peking Union Medical College Hospital Condition: Endometrial Cancer
Back to Endometrial Cancer

Phase 2 Endometrial Cancer Trial, Recruiting

NCT06562166
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 80 years old
  • People who have been confirmed through laboratory testing to have cervical cancer of a specific type called squamous cell carcinoma
  • People whose cervical cancer has been staged (using the 2018 FIGO system) as Stage Ib3, II, IIIB, or IIIC1
  • People whose treatment plan includes a full course of pelvic radiation therapy combined with platinum-based chemotherapy (cisplatin or carboplatin) given at the same time, for at least 5 rounds
  • People with a general health and activity level rated between 0 and 2 on a standard medical scale (meaning able to carry out at least some daily activities) (confirm with trial site)
  • People with a life expectancy of more than 6 months
  • People who are able to lie still for more than 30 minutes
  • People who are willing to participate and able to sign the consent form on their own
  • People whose recent blood test results (taken within 14 days before joining) meet specific levels for blood cell counts, kidney function, and liver function (confirm with trial site for exact values)
  • People who have completed all required baseline health checks before the trial begins
  • People who are able to attend regular follow-up appointments

Who may not be able to join:

  • People who have previously received radiotherapy or chemotherapy
  • People who have already had surgery to remove the cervical cancer
  • People with a past history of any other cancer
  • People who are pregnant or breastfeeding
  • People with serious uncontrolled conditions affecting the heart, kidneys, digestive system, lungs, blood, or nervous system

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 15801390180

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
5 September 2024
Est. completion
1 August 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Acute non-hematological toxicity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov